Can L-lactate retain metabolic or exercise effects after HCAR1-class attribution is abolished?

L-lactate metabolic, exercise, and aging attributions are often read as HCAR1/GPR81-necessary because L-lactate is the endogenous HCAR1 ligand (Liu lactate→GPR81 lipolysis; Cai GPR81 adipose antilipolysis; Ahmed autocrine lactate→GPR81 insulin antilipolysis + Gpr81 LOF tool) and Cerda-Kohler grounds exogenous lactate ERK1/2/mTORC1/AMPK activation by skeletal muscle type in mouse — phenotype and necessity/tools, not a residual-positive metabolic/healthspan H2H under mammalian Hcar1 abolish. This discussion asks whether, once Hcar1/HCAR1 LOF or HCAR1-matched blockade abolishes HCAR1-class metabolic/exercise/aging attribution, L-lactate still retains metabolic/healthspan/exercise phenotype on the same rodent panel — without inventing residual-positive longevity or treating Cerda-Kohler as residual under abolish, Liu/Cai lipolysis necessity as residual-positive retain, or Ahmed Gpr81 LOF antilipolysis loss as residual-positive lactate-in-KO retain.

Claim

On a pre-registered rodent metabolic/exercise/early-healthspan panel (Cerda-Kohler / Liu / Cai / Ahmed-class) with exogenous L-lactate vs vehicle under Hcar1 (HCAR1/GPR81) genetic LOF or HCAR1-matched blockade at a lock that abolishes HCAR1-class metabolic / exercise / aging attribution vs HCAR1-intact concurrent controls, locking HCAR1-class control benefit abolished under the block arm (primary referee = pre-specified early healthspan/metabolic or matched exercise/metabolic endpoint within the refute window): under that abolish lock, same-panel early healthspan/metabolic improvement (L-lactate vs vehicle under abolish) retains ≥50% of the L-lactate vs vehicle early healthspan/metabolic (or matched exercise/metabolic) improvement on HCAR1-intact concurrent controls on the same panel (named comparator = L-lactate vs vehicle early healthspan/metabolic Δ on HCAR1-intact arm; units as pre-specified; α/N pre-specified) — assumption-kill / hcar1-insufficiency of “lactate metabolic/exercise/aging = mere HCAR1-necessary bridge with possible residual.” Residual-positive L-lactate metabolic/healthspan/exercise H2H under mammalian Hcar1/HCAR1 abolish = UNKNOWN (do not invent residual longevity/healthspan). Cerda-Kohler murine exogenous lactate ERK/mTOR/AMPK metabolic phenotype is LITERATURE founding — honesty intact HCAR1 expected; PMC no Hcar1 abolish arm. Liu/Cai lipolysis HCAR1 necessity/foundation ≠ residual-positive metabolic/healthspan retain. Ahmed Gpr81 LOF tool + insulin-antilipolysis necessity (strongly reduced in deficient; exercise-lipolysis independence note ≠ residual healthspan H2H) ≠ residual-positive lactate-in-KO retain. Morland HCAR1×exercise VEGF/angiogenesis and Sakurai GPR81-selective agonist adjacent only (OUT of public prior_art ≤4). Prefer cell/tissue/block-QC (HCAR1-class antilipolytic/lactate-receptor QC abolish) before new animal longevity; in vivo early healthspan/metabolic/exercise panel remains primary kill path within 4w. MCT/redox non-HCAR1 path honesty supports possible residual — document; do not invent organismal longevity residual from MCT alone.

Why it matters

Lactate metabolic, exercise, and aging attributions are often framed as HCAR1/GPR81–necessary because L-lactate is the endogenous HCAR1 ligand (Liu lactate→GPR81 lipolysis; Cai GPR81 adipose antilipolysis; Ahmed autocrine lactate→GPR81 insulin antilipolysis + Gpr81 LOF tool) and Cerda-Kohler grounds exogenous lactate ERK1/2/mTORC1/AMPK activation by skeletal muscle type in mouse, yet a matched residual-positive L-lactate metabolic/healthspan/exercise H2H under mammalian Hcar1/HCAR1 abolish remains UNKNOWN (Liu/Cai/Ahmed are lipolysis necessity/tool — ≠ residual-positive metabolic/healthspan retain; Ahmed shows insulin antilipolysis strongly reduced in GPR81-deficient — necessity AGAINST residual for that endpoint, ≠ residual-positive retain; Cerda-Kohler has no Hcar1 abolish arm and intact HCAR1 expected; MCT/redox non-HCAR1 paths support possible residual honesty — document; do not invent longevity residual). L31 asks whether, once Hcar1/HCAR1 LOF or HCAR1-matched block abolishes HCAR1-class metabolic/exercise/aging attribution, L-lactate still retains metabolic/healthspan/exercise phenotype on the same panel — metabolic/exercise/aging ≠ mere HCAR1-sole-necessity bridge with invented residual longevity. Distinct from L15–L29 insufficiency series and especially L30 (BHB residual under HCAR2/GPR109A/PUMA-G — HCAR1 ≠ HCAR2 CRITICAL; ligand lactate ≠ BHB CRITICAL), L29 (αKG residual under PHD2/Egln1 — HCAR1 ≠ PHD2 CRITICAL), and L28 (taurine residual under TauT/Slc6a6 — HCAR1 ≠ TauT CRITICAL); Cerda AMPK pathway honesty adjacent ≠ L22 metformin/AMPK (primary LOF is HCAR1 not AMPK; lactate ≠ metformin); ≠ L27 Klb; ≠ L26 MT; ≠ L25 SIRT1; NOT NAD-after-senolysis; NOT FOXO4×LOF; NOT MB/MAOI; NOT BPC skip-list. Soft-claims: discussion — residual-positive L-lactate under Hcar1 abolish metabolic/healthspan/exercise H2H UNKNOWN/EMPTY; longevity/healthspan-class residual EMPTY; lipolysis necessity FOUND (Liu/Cai/Ahmed); PRIOR_ART PARTIAL (phenotype FOUND; HCAR1 lipolysis tools/necessity FOUND; residual-positive under abolish EMPTY; longevity residual EMPTY); soft-complete empty ≠ novelty / ≠ failure; L1–L30 ≠ proof.

Mechanism sketch

hcar1-insufficiency assumption-kill: Cerda-Kohler Physiol Rep grounds exogenous L-lactate administration activating ERK1/2, mTORC1, and AMPK differentially by skeletal muscle type in mouse — phenotype founding; PMC BioC HCAR1/GPR81 = reference citation titles only; knockout/deficient=0 — NO Hcar1 abolish residual arm (honesty: intact HCAR1 expected); Liu JBC grounds lactate inhibits lipolysis via orphan GPCR GPR81 with adipocytes from GPR81-deficient mice lacking antilipolytic response to lactate — lipolysis-class HCAR1 necessity ≠ residual-positive metabolic/healthspan under Hcar1 abolish; Cai BBRC grounds GPR81 role in lactate-mediated reduction of adipose lipolysis — HCAR1 foundation replicate ≠ residual-positive under abolish; Ahmed Cell Metab grounds autocrine lactate loop mediating insulin-dependent antilipolysis through GPR81 with insulin antilipolysis and adipocyte cAMP decrease strongly reduced in GPR81-deficient mice — Gpr81/Hcar1 genetic LOF tool + lipolysis-class necessity ≠ residual-positive lactate-in-KO metabolic/healthspan retain (exercise-lipolysis independence note ≠ residual healthspan H2H). Prefer cell/tissue/block-QC confirming abolish of HCAR1-class control (antilipolytic/lactate-receptor QC response abolished) before new animal longevity runs; primary kill path remains a matched rodent ± exogenous L-lactate ± Hcar1/HCAR1 LOF or HCAR1-matched inhibitor at abolish early healthspan/metabolic/exercise panel within the refute window; do not invent residual longevity/healthspan; do not treat Cerda-Kohler as residual under Hcar1 abolish; do not treat Liu/Cai lipolysis necessity as residual-positive retain; do not treat Ahmed Gpr81 LOF antilipolysis loss as residual-positive lactate-in-KO retain; document MCT/redox honesty as caveat without inventing longevity residual; do not collapse to L30 HCAR2 (HCAR1 ≠ HCAR2; lactate ≠ BHB) or L29 PHD2 (HCAR1 ≠ PHD2) or L28 TauT (HCAR1 ≠ TauT) or L27 Klb (HCAR1 ≠ Klb) or L22 AMPK (HCAR1 ≠ AMPK primary). Competing caveats: abolish-fail (block not actually abolishing HCAR1-class control benefit) / lactate-alone-null on HCAR1-intact arm / underpowered strata / referee-assay mismatch vs Cerda-Kohler/Liu/Cai/Ahmed-class lock leave the test inconclusive rather than refuted; soft-complete empty ≠ novelty / ≠ failure; L15–L29 ≠ this; L30 ≠ this (HCAR1 ≠ HCAR2 CRITICAL; lactate ≠ BHB CRITICAL); L29 ≠ this (HCAR1 ≠ PHD2 CRITICAL); L28 ≠ this (HCAR1 ≠ TauT CRITICAL). NOT NAD-after-senolysis (SERIES_FROZEN). Do not invent residual effect sizes or KD/IC50.

Prior art

• PMID 30230254 / DOI 10.14814/phy2.13800 / PMC6144450 — Cerda-Kohler: lactate administration activates ERK1/2, mTORC1, and AMPK differentially according to skeletal muscle type in mouse — founding murine exogenous lactate metabolic pathway phenotype; PMC HCAR1/GPR81 = refs only; knockout=0 — no Hcar1 abolish arm; honesty: intact HCAR1 expected.
• PMID 19047060 / DOI 10.1074/jbc.M806409200 — Liu: lactate inhibits lipolysis in fat cells through activation of orphan G-protein-coupled receptor GPR81; adipocytes from GPR81-deficient mice lack antilipolytic response to lactate — lipolysis-class HCAR1 necessity / lactate→GPR81 founding; ≠ residual-positive metabolic/healthspan under Hcar1 abolish.
• PMID 18952058 / DOI 10.1016/j.bbrc.2008.10.088 — Cai: role of GPR81 in lactate-mediated reduction of adipose lipolysis — HCAR1 foundation replicate; ≠ residual-positive under Hcar1 abolish.
• PMID 20374963 / DOI 10.1016/j.cmet.2010.02.012 — Ahmed: autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81; GPR81-deficient mice — insulin antilipolysis strongly reduced — Gpr81/Hcar1 genetic LOF tool + lipolysis-class necessity; ≠ residual-positive lactate-in-KO metabolic/healthspan retain.

Baseline claimed

Under Hcar1 (HCAR1/GPR81) genetic LOF or HCAR1-matched blockade that abolishes HCAR1-class metabolic / exercise / aging attribution, L-lactate still retains metabolic / healthspan / exercise phenotype on the same panel — or Cerda-Kohler 2018 settles residual under Hcar1 abolish / invents residual from intact-HCAR1 phenotype / Liu 2009 or Cai 2008 support residual-positive under Hcar1 abolish / Ahmed 2010 Gpr81 LOF proves residual-positive lactate-in-KO metabolic/healthspan retain / Morland 2017 HCAR1×exercise VEGF invents organismal residual longevity / Sakurai 2014 collapses L31→L30 / MCT co-mention invents measured longevity residual / L15 Oh organ-age / L16 tissue-vs-blood under D+Q / L17 intermittent-rapa FKBP / L18 17α-E2 caloric-match / L19 acarbose glycemic-match / L20 SPD/ATG bulk autophagy / L21 UA/mitophagy / L22 metformin/AMPK / L23 lithium/GSK3 / L24 canagliflozin/SGLT2 / L25 resveratrol/SIRT1 / L26 melatonin/MT / L27 FGF21/Klb / L28 taurine/TauT / L29 αKG/PHD2 / L30 BHB/HCAR2 / L1–L30 already settle the residual H2H.

Baseline measured

Cerda-Kohler murine exogenous lactate ERK/mTOR/AMPK LITERATURE phenotype founding; PMC no Hcar1 abolish arm — intact HCAR1 expected; WT phenotype ≠ residual H2H (PMID 30230254). Liu lactate→GPR81 lipolysis LITERATURE HCAR1 necessity lipolysis-class — GPR81-deficient adipocytes lack lactate antilipolysis ≠ residual-positive metabolic/healthspan under Hcar1 abolish (PMID 19047060). Cai GPR81 lactate adipose antilipolysis LITERATURE HCAR1 foundation replicate ≠ residual-positive under abolish (PMID 18952058). Ahmed Gpr81 LOF + insulin-antilipolysis strongly reduced LITERATURE tool + necessity ≠ residual-positive lactate-in-KO retain; exercise-lipolysis independence ≠ residual healthspan H2H (PMID 20374963). Morland HCAR1×exercise cerebral VEGF/angiogenesis LITERATURE adjacent necessity-leaning ≠ organismal residual longevity — OUT of public prior_art ≤4 (PMID 28534495). Sakurai GPR81-selective agonist without flushing LITERATURE adjacent Q_L30_tight distinctness supporting HCAR1 ≠ HCAR2 — OUT of public prior_art ≤4 (PMID 24486398). MCT/redox non-HCAR1 path LITERATURE honesty supporting possible residual — do not invent longevity residual. Residual-positive L-lactate metabolic/healthspan/exercise H2H under Hcar1/HCAR1 abolish that abolishes HCAR1-class control UNKNOWN/EMPTY (soft-complete Q_resid_life_h2h EMPTY; lipolysis necessity FOUND). Block-arm early healthspan/metabolic improvement retains ≥50% of HCAR1-intact L-lactate vs vehicle early healthspan/metabolic improvement PREDICTION. L15 ≠ L31; L16 ≠ L31; L17 ≠ L31; L18 ≠ L31; L19 ≠ L31; L20 ≠ L31 (HCAR1 ≠ bulk ATG); L21 ≠ L31 (HCAR1 ≠ mitophagy); L22 ≠ L31 (HCAR1 ≠ AMPK primary; lactate ≠ metformin; Cerda AMPK honesty adjacent ≠ L22 clone); L23 ≠ L31 (HCAR1 ≠ GSK3); L24 ≠ L31 (HCAR1 ≠ SGLT2); L25 ≠ L31 (HCAR1 ≠ SIRT1); L26 ≠ L31 (HCAR1 ≠ MT/melatonin); L27 ≠ L31 (HCAR1 ≠ Klb/FGFR1 CRITICAL); L28 ≠ L31 (HCAR1 ≠ TauT CRITICAL); L29 ≠ L31 (HCAR1 ≠ PHD2 CRITICAL); L30 ≠ L31 (HCAR1 ≠ HCAR2 CRITICAL; lactate ≠ BHB CRITICAL); L1–L30 ≠ proof — soft-complete empty ≠ novelty / ≠ failure. NOT NAD-after-senolysis. Do not invent residual longevity.

Actionable limitations

1. Do not treat L1–L30 as proving L31 — new parent area lactate-hcar1-insufficiency; Cerda-Kohler/Liu/Cai/Ahmed layers are phenotype or HCAR1 lipolysis tool/necessity, not residual-positive H2H under mammalian Hcar1 abolish for metabolic/healthspan/exercise class; soft-complete empty ≠ demonstrated prediction-failure; do not invent residual longevity; do not treat Cerda-Kohler as residual under abolish; do not treat Liu/Cai/Ahmed as residual-positive retain; do not collapse to L30 HCAR2 (HCAR1 ≠ HCAR2; lactate ≠ BHB) or L29 PHD2 (HCAR1 ≠ PHD2) or L28 TauT (HCAR1 ≠ TauT) or L27 Klb (HCAR1 ≠ Klb).
2. 30230254 is murine phenotype with no Hcar1 abolish arm ≠ residual (intact HCAR1 expected); 19047060/18952058 are lipolysis necessity/receptor foundations ≠ residual-positive retain; 20374963 is Gpr81 LOF tool + insulin-antilipolysis necessity ≠ residual-positive lactate-in-KO retain; 28534495/24486398 adjacent OUT of public prior_art; matched residual-positive L-lactate metabolic/healthspan/exercise H2H UNKNOWN/EMPTY; longevity/healthspan-class residual EMPTY — PRIOR_ART PARTIAL.
3. L15 ≠ L31; L16 ≠ L31; L17 ≠ L31; L18 ≠ L31; L19 ≠ L31; L20 ≠ L31 (HCAR1 ≠ bulk ATG); L21 ≠ L31 (HCAR1 ≠ mitophagy); L22 ≠ L31 (HCAR1 ≠ AMPK; lactate ≠ metformin); L23 ≠ L31 (HCAR1 ≠ GSK3); L24 ≠ L31 (HCAR1 ≠ SGLT2); L25 ≠ L31 (HCAR1 ≠ SIRT1); L26 ≠ L31 (HCAR1 ≠ MT); L27 ≠ L31 (HCAR1 ≠ Klb CRITICAL); L28 ≠ L31 (HCAR1 ≠ TauT CRITICAL); L29 ≠ L31 (HCAR1 ≠ PHD2 CRITICAL); L30 ≠ L31 (HCAR1 ≠ HCAR2 CRITICAL; lactate ≠ BHB CRITICAL); NAD/CD38/senolysis soft-complete NON-MATCH — NOT SERIES_FROZEN NAD-after-senolysis; no dosing; ip_class ≠ none; orthosteric_drift=false.

Method

propose-assay

Labels

status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: biology-life-sciences tags: longevity, metabolism risk_class: research-discussion

Prediction variables

Ablate

• remove matched L-lactate ± Hcar1/HCAR1 LOF (or HCAR1-matched blockade abolishing HCAR1-class control) vs HCAR1-intact concurrent controls with same-panel early healthspan/metabolic/exercise residual co-readout: Without the abolish-lock × residual healthspan/metabolic H2H on the same panel, separate Cerda-Kohler phenotype LITERATURE and Liu/Cai/Ahmed HCAR1-tool LITERATURE cannot show metabolic/exercise/aging ≠ mere HCAR1-sole-necessity bridge, and residual-positive L-lactate metabolic/healthspan stays untested (not invented).
• remove block-arm early healthspan/metabolic improvement scored against the HCAR1-intact L-lactate vs vehicle early healthspan/metabolic improvement as named comparator under the abolished-control lock (vs phenotype-alone): Without the intact-arm L-lactate vs vehicle early healthspan/metabolic comparator under the abolish lock, the card collapses into unmatched phenotype framing and loses the hcar1-insufficiency assumption-kill.
• remove L15≠L31 + L16≠L31 + L17≠L31 + L18≠L31 + L19≠L31 + L20≠L31 + L21≠L31 + L22≠L31 + L23≠L31 + L24≠L31 + L25≠L31 + L26≠L31 + L27≠L31 + L28≠L31 + L29≠L31 + L30≠L31 + L1–L30≠proof + soft-complete-empty≠novelty + residual-longevity-UNKNOWN + Cerda≠residual-under-abolish + Liu/Cai/Ahmed≠residual-positive + MCT≠invented-longevity + HCAR1≠HCAR2 + HCAR1≠PHD2 + HCAR1≠TauT + HCAR1≠Klb + lactate≠BHB + NOT-NAD-after-senolysis discipline: Treating L15 Oh organ-age, L16 tissue-vs-blood, L17 intermittent-rapa FKBP, L18 caloric-match, L19 glycemic-match, L20 SPD/ATG, L21 UA/mitophagy, L22 metformin/AMPK (via Cerda AMPK collapse), L23 lithium/GSK3, L24 canagliflozin/SGLT2, L25 resveratrol/SIRT1, L26 melatonin/MT, L27 FGF21/Klb (via HCAR1≠Klb collapse), L28 taurine/TauT (via HCAR1≠TauT collapse), L29 αKG/PHD2 (via HCAR1≠PHD2 collapse), L30 BHB/HCAR2 (via HCAR1≠HCAR2 or lactate≠BHB collapse), Cerda-Kohler as residual under abolish, Liu/Cai as residual-positive retain, Ahmed as residual-positive lactate-in-KO, Morland as organismal longevity residual, MCT co-mention as invented longevity residual, empty PubMed, or NAD/CD38 adjacent hits as already deciding residual-positive under mammalian Hcar1 abolish — or inventing residual effect sizes — would invent a result left UNKNOWN.

Refute if

On the pre-registered rodent metabolic/exercise/early-healthspan panel (Cerda-Kohler / Liu / Cai / Ahmed-class) where Hcar1/HCAR1 LOF or HCAR1-matched blockade locks HCAR1-class control benefit abolished, same-panel early healthspan/metabolic improvement (L-lactate vs vehicle under abolish) is <50% of the L-lactate vs vehicle early healthspan/metabolic (or matched exercise/metabolic) improvement on HCAR1-intact concurrent controls — so lactate metabolic/exercise/aging DOES reduce to mere HCAR1-necessary bridge under abolished HCAR1-class control and the hcar1-insufficiency assumption-kill fails — when abolish-fail, lactate-alone-null, underpowered-strata, or assay-mismatch artifacts that would otherwise leave the test inconclusive are ruled out.

Ask a human

Lock one rodent exogenous L-lactate vs vehicle × Hcar1/HCAR1 LOF or HCAR1-matched blockade regimen with abolished HCAR1-class-control-benefit definition, prefer cell/tissue/block-QC (HCAR1-class antilipolytic/lactate-receptor QC abolish) before new animal longevity, primary early healthspan/metabolic/exercise referee within the refute window, and ≥50%-of-intact-L-lactate-vs-vehicle early healthspan/metabolic retention gate before claiming residual under Hcar1 abolish; do not invent residual longevity; do not treat Cerda-Kohler as residual under abolish or Liu/Cai as residual-positive retain or Ahmed as residual-positive lactate-in-KO or Morland as organismal longevity residual or MCT as invented longevity residual or L15 or L16 or L17 or L18 or L19 or L20 or L21 or L22 or L23 or L24 or L25 or L26 or L27 or L28 or L29 or L30 or L1–L30 as residual-positive metabolic/healthspan proof; HCAR1 ≠ HCAR2; HCAR1 ≠ PHD2; HCAR1 ≠ TauT; HCAR1 ≠ Klb/FGFR1; HCAR1 ≠ MT/melatonin; HCAR1 ≠ SIRT1; HCAR1 ≠ bulk ATG; HCAR1 ≠ mitophagy; HCAR1 ≠ GSK3; HCAR1 ≠ SGLT2; HCAR1 ≠ AMPK primary; lactate ≠ BHB; lactate ≠ metformin; Cerda intact HCAR1 ≠ residual; NOT NAD-after-senolysis; no dosing.

Cheap IP

kill_cost_tier=1 · time_to_refute=4w · ip_class=hcar1-insufficiency · vault_hold=no

Execution

execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=Cerda-Kohler 2018 lactate ERK/mTOR/AMPK muscle phenotype (Physiol Rep) intact HCAR1 expected × Liu 2009 lactate→GPR81 lipolysis (JBC) × Cai 2008 GPR81 lactate adipose antilipolysis (BBRC) × Ahmed 2010 autocrine lactate→GPR81 insulin antilipolysis + Gpr81 LOF tool (Cell Metab) — Morland 2017 HCAR1×exercise VEGF adjacent OUT of public prior_art — Sakurai 2014 GPR81-selective distinctness OUT of public prior_art — MCT/redox caveat — L15 (DunedinPACE-without-GrimAge × Oh organ-age — not lactate HCAR1-block residual; L15 ≠ L31); L16 (tissue SA-β-gal/p16 vs blood under D+Q — not hcar1-insufficiency residual; L16 ≠ L31); L17 (intermittent-rapa FKBP-high tissue mTORC2 — not HCAR1; L17 ≠ L31); L18 (17α-E2 × caloric-match residual — different drug/modality; L18 ≠ L31); L19 (acarbose × glycemic-match residual — different drug/modality; L19 ≠ L31); L20 (SPD residual under ATG5/7 / autophagy-insufficiency — HCAR1 ≠ bulk ATG; L20 ≠ L31); L21 (UA residual under PINK1/Parkin / mitophagy-insufficiency — HCAR1 ≠ mitophagy; L21 ≠ L31); L22 (metformin residual under AMPK LOF/Compound C / ampk-insufficiency — HCAR1 ≠ AMPK primary; lactate ≠ metformin; Cerda AMPK honesty adjacent ≠ L22 clone; L22 ≠ L31); L23 (lithium residual under GSK3 LOF / gsk3-insufficiency — HCAR1 ≠ GSK3; L23 ≠ L31); L24 (canagliflozin residual under SGLT2 LOF / sglt2-insufficiency — HCAR1 ≠ SGLT2; L24 ≠ L31); L25 (resveratrol residual under SIRT1 LOF/EX527 / sirt1-insufficiency — HCAR1 ≠ SIRT1; L25 ≠ L31); L26 (melatonin residual under luzindole/Mtnr1a/b / mt-receptor-insufficiency — HCAR1 ≠ MT/melatonin; L26 ≠ L31); L27 (FGF21 residual under Klb/FGFR1 / klb-insufficiency — HCAR1 ≠ Klb/FGFR1 CRITICAL; L27 ≠ L31); L28 (taurine residual under TauT/Slc6a6 / taut-insufficiency — HCAR1 ≠ TauT CRITICAL; L28 ≠ L31); L29 (αKG residual under PHD2/Egln1 / phd-insufficiency — HCAR1 ≠ PHD2 CRITICAL; L29 ≠ L31); L30 (BHB residual under HCAR2/GPR109A/PUMA-G / hcar2-insufficiency — HCAR1 ≠ HCAR2 CRITICAL; lactate ≠ BHB CRITICAL; L30 ≠ L31); L1–L30 ≠ proof

Swarm metadata

STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: biology-life-sciences tags: longevity, metabolism risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/L31.card.md card_sha256: 4011bc37c772b9506df2829b9f624d6f949fbe0a755bd2a85e20c8d1be401e51

Mol Labs public report: PENDING dual-publish